Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins

Biomaterials

Volumn 34, Issue 1, 2013, Pages 306-319

  Zhang, Wenli ^a   He, Hongliang ^a   Liu, Jianping ^a   Wang, Ji ^a   Zhang, Suyang ^a   Zhang, Shuangshuang ^a   Wu, Zimei ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antiatherogenic efficacies; Atherosclerotic lesions targeting effects; HDL; Remodeling behaviors; Tanshinone IIA discoidal recombinant HDL; Tanshinone IIA spherical recombinant HDL

Indexed keywords

ANTIATHEROGENIC EFFICACIES; ATHEROSCLEROTIC LESIONS; HDL; REMODELING BEHAVIORS; TANSHINONE II A;

BIOMIMETICS; LIPOSOMES; LOADING; PHARMACOKINETICS; PHOSPHOLIPIDS; SODIUM;

SPHERES;

HIGH DENSITY LIPOPROTEIN; LIPOSOME; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TANSHINONE IIA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; EX VIVO STUDY; FILM; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; RABBIT;

ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; AZO COMPOUNDS; BIOMIMETIC MATERIALS; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL; COLLAGEN; DISEASE MODELS, ANIMAL; DITERPENES, ABIETANE; LIPOPROTEINS; LIPOPROTEINS, HDL; MACROPHAGES; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RABBITS; RECOMBINANT PROTEINS; STATIC ELECTRICITY; TRANSCRIPTION FACTOR RELA;

ORYCTOLAGUS CUNICULUS;

EID: 84868140945     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.058     Document Type: Article

References (47)

1. Tsompanidi E.M., Brinkmeier M.S., Fotiadou E.H., Giakoumi S.M., Kypreos K.E. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2010, 208:3-9.
2. Conca P., Franceschini G. Synthetic HDL as a new treatment for atherosclerosis regression: has the time come?. Nutr Metabol Cardiovasc Dis 2008, 18:329-335.
3. Rohrer L., Ohnsorg P.M., Lehner M., Landolt F., Rinninger F., von Eckardstein A. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ Res 2009, 104:1142-1150.
4. Rigotti A., Krieger M. The HDL receptor SR-BI. High density lipoproteins, dyslipidemia, and coronary heart disease 2010, 103-110. Springer Science, New York. E.J. Schaefer (Ed.).
5. Zhang W.L., Gu X., Bai H., Yang R.H., Dong C.D., Liu J.P. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm 2010, 391:313-321.
6. Rensen P.C.N., de Vrueh R.L.A., Kuiper J., Bijsterbosch M.K., Biessen E.A.L., van Berkel T.J.C. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001, 47:251-276.
7. Lacko A.G., Nair M., Prokai L., McConathy W.J. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expet Opin Drug Deliv 2007, 4:665-675.
8. Corbin I.R., Chen J., Cao W., Li H., Lund-Katz S., Zheng G. Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers. J Biomed Nanotechnol 2007, 3:367-376.
9. Xu S., Little P.J., Lan T., Huang Y., Le K., Wu X., et al. Tanshinone II-a attenuates and stabilizes atherosclerotic plaques in apolipoprotein-e knockout mice fed a high cholesterol diet. Arch Biochem Biophys 2011, 515:72-79.
10. Gao S., Liu Z., Li H., Little P.J., Liu P., Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 2011, 220:3-10.
11. Xu S., Liu Z., Huang Y., Le K., Tang F., Huang H., et al. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation. Transl Res 2012, 160:114-124.
12. Sun D., Shen M., Li J., Li W., Zhang Y., Zhao L., et al. Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol 2011, 10:4-12.
13. Li J., Liu P., Liu J.P., Zhang W.L., Yang J.K., Fan Y.Q. Novel tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2011, 80:426-432.
14. Li Q., Wang Y., Feng N., Fan Z., Sun J., Nan Y. Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma. J Drug Target 2008, 16:725-732.
15. Chu T., Zhang Q., Li H., Ma W., Zhang N., Jin H., et al. Development of intravenous lipid emulsion of tanshinone IIA and evaluation of its anti-hepatoma activity in vitro. Int J Pharm 2011, 424:76-88.
16. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469-478.
17. Skajaa T., Cormode D.P., Jarzyna P.A., Delshad A., Blachford C., Barazza A., et al. The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials 2011, 32:206-213.
18. Frias J.C., Williams K.J., Fisher E.A., Fayad Z.A. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004, 126:16316-16317.
19. Zhang W.L., Xiao Y., Liu J.P., Wu Z.M., Gu X., Xu Y.M., et al. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int J Pharm 2011, 419:314-321.
20. Zhang W.L., Li J., Liu J.P., Wu Z.M., Xu Y.M., Wang J. Tanshinone IIA-loaded reconstituted high density lipoproteins: atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits. Pharmazie 2012, 67:324-330.
21. Jain S.K., Chaurasiya A., Gupta Y., Jain A., Dagur P., Joshi B., et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 2008, 25:289-297.
22. Li C.L., Cui J.X., Wang C.X., Li Y.G., Zhang H.W., Wang J.X., et al. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 2008, 70:657-665.
23. Holmquist L. Selective extraction of lecithin: cholesterol acyltransferase (EC 2.3. 1.43) from human plasma. J Biochem Biophys Methods 2002, 52:63-68.
24. Jia J.T., Xiao Y., Liu J.P., Zhang W.L., He H.L., Chen L., et al. Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins. J Pharm Sci 2012, 101:2900-2908.
25. Plenz G., Dorszewski A., Breithardt G., Robenek H. Expression of type VIII collagen after cholesterol diet and injury in the rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 1999, 19:1201-1209.
26. Ronald J.A., Chen J.W., Chen Y., Hamilton A.M., Rodriguez E., Reynolds F., et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009, 120:592-599.
27. Fukuchi Y., Miura Y., Nabeno Y., Kato Y., Osawa T., Naito M. Immunohistochemical detection of oxidative stress biomarkers, dityrosine and N (epsilon)-(hexanoyl) lysine, and C-reactive protein in rabbit atherosclerotic lesions. J Atheroscler Thromb 2008, 15:185-192.
28. Chen W.Q., Zhang L., Liu Y.F., Chen L., Ji X.P., Zhang M., et al. Prediction of atherosclerotic plaque ruptures with high-frequency ultrasound imaging and serum inflammatory markers. Am J Physiol Heart Circ Physiol 2007, 293:H2836-H2844.
29. Park K., Hong H.Y., Moon H.J., Lee B.H., Kim I.S., Kwon I.C., et al. A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. J Control Release 2008, 128:217-223.
30. Dong B., Zhang C., Feng J.B., Zhao Y.X., Li S.Y., Yang Y.P., et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:1270-1276.
31. von Vietinghoff S., Koltsova E.K., Mestas J., Diehl C.J., Witztum J.L., Ley K. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol 2011, 57:2194-2204.
32. Lindeman J.H.N., Ashcroft B.A., Beenakker J.W.M., Van Es M., Koekkoek N.B.R., Prins F.A., et al. Distinct defects in collagen microarchitecture underlie vessel-wall failure in advanced abdominal aneurysms and aneurysms in Marfan syndrome. Proc Natl Acad Sci U S A 2010, 107:862-865.
33. Hernández-Presa M.A., Bustos C., Ortego M., Tuñón J., Ortega L., Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-κB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998, 153:1825-1837.
34. Vidal C., Gómez-Hernández A., Sánchez-Galán E., González A., Ortega L., Gómez-Gerique J.A., et al. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther 2007, 320:108-116.
35. Buffoli B., Pechánová O., Kojšová S., Andriantsitohaina R., Giugno L., Bianchi R., et al. Provinol prevents CsA-induced nephrotoxicity by reducing reactive oxygen species, iNOS, and NF-kB expression. J Histochem Cytochem 2005, 53:1459-1468.
36. Cimini M., Boughner D.R., Ronald J.A., Aldington L., Rogers K.A. Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. J Heart Valve Dis 2005, 14:365-375.
37. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007, 9:128-147.
38. Barter P., Kastelein J., Nunn A., Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003, 168:195-211.
39. Nakashima Y., Fujii H., Sumiyoshi S., Wight T.N., Sueishi K. Early human atherosclerosis accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007, 27:1159-1165.
40. Tearney G.J., Yabushita H., Houser S.L., Aretz H.T., Jang I.K., Schlendorf K.H., et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 2003, 107:113-119.
41. VanderLaan P.A., Reardon C.A., Getz G.S. Site specificity of atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:12-22.
42. Moulton K.S., Olsen B.R., Sonn S., Fukai N., Zurakowski D., Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004, 110:1330-1336.
43. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
44. Shin W.S., Szuba A., Rockson S.G. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002, 160:91-102.
45. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297:499-508.
46. Patel S., Drew B.G., Nakhla S., Duffy S.J., Murphy A.J., Barter P.J., et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009, 53:962-971.
47. Nicholls S.J., Dusting G.J., Cutri B., Bao S., Drummond G.R., Rye K.A., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005, 111:1543-1550.